- Home
- BW vs IPHA Comparison
BW vs IPHA Comparison
Compare BW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BW
- IPHA
- Stock Information
- Founded
- BW 1867
- IPHA 1999
- Country
- BW United States
- IPHA France
- Employees
- BW N/A
- IPHA N/A
- Industry
- BW Building Products
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- BW Industrials
- IPHA Health Care
- Exchange
- BW Nasdaq
- IPHA Nasdaq
- Market Cap
- BW 95.7M
- IPHA 160.1M
- IPO Year
- BW N/A
- IPHA 2019
- Fundamental
- Price
- BW $1.05
- IPHA $1.74
- Analyst Decision
- BW Buy
- IPHA Strong Buy
- Analyst Count
- BW 2
- IPHA 1
- Target Price
- BW $3.50
- IPHA $11.00
- AVG Volume (30 Days)
- BW 1.0M
- IPHA 11.2K
- Earning Date
- BW 08-07-2025
- IPHA 09-11-2025
- Dividend Yield
- BW N/A
- IPHA N/A
- EPS Growth
- BW N/A
- IPHA N/A
- EPS
- BW N/A
- IPHA N/A
- Revenue
- BW $734,239,000.00
- IPHA $20,831,349.00
- Revenue This Year
- BW $5.81
- IPHA $209.83
- Revenue Next Year
- BW $9.24
- IPHA $83.15
- P/E Ratio
- BW N/A
- IPHA N/A
- Revenue Growth
- BW 12.90
- IPHA N/A
- 52 Week Low
- BW $0.22
- IPHA $1.29
- 52 Week High
- BW $2.99
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- BW 55.61
- IPHA 42.70
- Support Level
- BW $0.99
- IPHA $1.71
- Resistance Level
- BW $1.10
- IPHA $1.90
- Average True Range (ATR)
- BW 0.07
- IPHA 0.08
- MACD
- BW -0.01
- IPHA 0.00
- Stochastic Oscillator
- BW 69.44
- IPHA 47.62
About BW Babcock & Wilcox Enterprises Inc.
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.